CERC-002, a human anti-LIGHT mAb reduces respiratory failure and death in hospitalized COVID-19 ARDS patients

David S. Perlin, Garry A. Neil, Colleen Anderson, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F. Ware, H. Jeffrey Wilkins
doi: https://doi.org/10.1101/2021.04.03.21254748

Article Information

doi 
https://doi.org/10.1101/2021.04.03.21254748
History 
  • April 7, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. David S. Perlin1,
  2. Garry A. Neil2,*,
  3. Colleen Anderson2,
  4. Inbal Zafir-Lavie2,
  5. Lori Roadcap2,
  6. Shane Raines2,
  7. Carl F. Ware3 and
  8. H. Jeffrey Wilkins2
  1. 1Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA
  2. 2Cerecor, Inc., Wayne, PA, USA
  3. 3Laboratory of Molecular Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
  1. ↵* Corresponding author; email: gneil{at}cerecor.com
Back to top
Posted April 07, 2021.
Download PDF
Data/Code
Email
CERC-002, a human anti-LIGHT mAb reduces respiratory failure and death in hospitalized COVID-19 ARDS patients
David S. Perlin, Garry A. Neil, Colleen Anderson, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F. Ware, H. Jeffrey Wilkins
medRxiv 2021.04.03.21254748; doi: https://doi.org/10.1101/2021.04.03.21254748
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area